Drug Interaction Report
1 drug interaction and 10 additional warnings found for the following 2 drugs:
- orforglipron
- trofinetide
Drug interactions
Moderate drug interactions
Moderate:trofinetide orforglipron
Applies to: trofinetide, orforglipron
Trofinetide may increase the blood levels and effects of orforglipron. You may need more frequent monitoring to safely use both medications.
You may be more likely to experience side effects while on this combination and should alert your healthcare provider immediately if you notice a severe pain in your stomach area that will not go away and/or severe or persistent stomach problems.
It is also important to report any signs or symptoms of low blood sugar (hypoglycemia) such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and/or rapid heartbeat.
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:Food/Lifestyle orforglipron
Applies to: orforglipron
Grapefruit juice may increase the blood levels of certain medications such as orforglipron.
You may want to limit your consumption of grapefruit and grapefruit juice during treatment with orforglipron. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication.
Contact your doctor if your condition changes or you experience increased side effects.
Orange juice is not expected to interact.
Disease interactions
9 potential interactionsApplies to: 9 conditions, including Diarrhea, Gastroparesis, Diabetes Mellitus, Liver Disease, and Dehydration.
Dehydration
Moderate:orforglipron
Orforglipron has a moderate potential interaction with Dehydration.
There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.
Diabetes Mellitus
Moderate:orforglipron
Orforglipron has a moderate potential interaction with Diabetes Mellitus.
Orforglipron lowers blood glucose and can cause hypoglycemia. In diabetic patients, blood glucose should be monitored before starting and during treatment with orforglipron.
Diabetic Retinopathy
Moderate:orforglipron
Orforglipron has a moderate potential interaction with Diabetic Retinopathy.
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Orforglipron has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy during treatment with orforglipron.
Diarrhea
Moderate:orforglipron
Orforglipron has a moderate potential interaction with Diarrhea.
There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.
Gastroparesis
Moderate:orforglipron
Orforglipron has a moderate potential interaction with Gastroparesis.
Use of orforglipron has been associated with gastrointestinal adverse reactions (sometimes severe). Orforglipron is not recommended in patients with severe gastroparesis.
Liver Disease
Moderate:orforglipron
Orforglipron has a moderate potential interaction with Liver Disease.
Orforglipron is not recommended for patients with severe liver dysfunction (Child-Pugh C). No dose adjustment is needed for patients with mild or moderate liver dysfunction (Child-Pugh A or B).
Multiple Endocrine Neoplasia Type II
Major:orforglipron
Orforglipron has a major potential interaction with Multiple Endocrine Neoplasia Type II.
Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Patients should be counseled regarding the potential risk for MTC with the use of orforglipron and should be informed of symptoms of thyroid tumors.
Thyroid Tumor
Major:orforglipron
Orforglipron has a major potential interaction with Thyroid Tumor.
Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Patients should be counseled regarding the potential risk for MTC with the use of orforglipron and should be informed of symptoms of thyroid tumors.
Vomiting
Moderate:orforglipron
Orforglipron has a moderate potential interaction with Vomiting.
There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.